Skip to main content
Premium Trial:

Request an Annual Quote

3M Developing Nucleic Acid Test Kits with Lumora's BART Technology

NEW YORK (GenomeWeb News) – 3M has entered into a joint development and licensing deal for use of Lumora's BART technology in developing nucleic acid test kits, the firms announced today.

Financial and other details of the agreement were not disclosed.

BART, which stands for Bioluminescent Assay in Real-Time, is a novel reporter system for use with isothermal nucleic acid amplification technologies as a tool in molecular diagnostics. In a statement, UK-based Lumora said that it is looking for other collaborative development and licensing partnerships "to bring its core technology to market in industrial sectors and clinical in vitro diagnostic applications."

In May the company announced it had raised about $2.1 million in second-stage funding, which would be used to accelerate its move in the clinical molecular diagnostics space with the BART technology.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.